164 related articles for article (PubMed ID: 34692726)
1. Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples.
Kuempers C; Jagomast T; Krupar R; Paulsen FO; Heidel C; Ribbat-Idel J; Idel C; Märkl B; Anlauf M; Berezowska S; Tiemann M; Bösmüller H; Fend F; Kalsdorf B; Bohnet S; Dreyer E; Sailer V; Kirfel J; Perner S
Front Med (Lausanne); 2021; 8():734901. PubMed ID: 34692726
[TBL] [Abstract][Full Text] [Related]
2. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
Blackhall F; Jao K; Greillier L; Cho BC; Penkov K; Reguart N; Majem M; Nackaerts K; Syrigos K; Hansen K; Schuette W; Cetnar J; Cappuzzo F; Okamoto I; Erman M; Langer SW; Kato T; Groen H; Sun Z; Luo Y; Tanwani P; Caffrey L; Komarnitsky P; Reinmuth N
J Thorac Oncol; 2021 Sep; 16(9):1547-1558. PubMed ID: 33607312
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of delta-like protein 3 combined with thyroid transcription factor-1 in small-cell lung cancer.
Yan LX; Liu YH; Li Z; Luo DL; Li YF; Yan JH; Zhang JT; Liu C; Liu XH; He J
Oncol Lett; 2019 Sep; 18(3):2254-2261. PubMed ID: 31452726
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
[TBL] [Abstract][Full Text] [Related]
6. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
Tanaka K; Isse K; Fujihira T; Takenoyama M; Saunders L; Bheddah S; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Jan; 115():116-120. PubMed ID: 29290251
[TBL] [Abstract][Full Text] [Related]
8. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
[TBL] [Abstract][Full Text] [Related]
9. Rovalpituzumab tesirine resistance: analysis of a corresponding small cell lung cancer and circulating tumor cell line pair.
Rath B; Plangger A; Krenbek D; Hochmair M; Stickler S; Tretter V; Hamilton G
Anticancer Drugs; 2022 Mar; 33(3):300-307. PubMed ID: 34924498
[TBL] [Abstract][Full Text] [Related]
10. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
[TBL] [Abstract][Full Text] [Related]
11. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
Johnson ML; Zvirbule Z; Laktionov K; Helland A; Cho BC; Gutierrez V; Colinet B; Lena H; Wolf M; Gottfried M; Okamoto I; van der Leest C; Rich P; Hung JY; Appenzeller C; Sun Z; Maag D; Luo Y; Nickner C; Vajikova A; Komarnitsky P; Bar J
J Thorac Oncol; 2021 Sep; 16(9):1570-1581. PubMed ID: 33823285
[TBL] [Abstract][Full Text] [Related]
12. Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer.
Bylsma LC; Pundole X; Ju CH; Hooda N; Movva N; Elkhouly E; Bebb G; Fryzek J; Martinez P; Balasubramanian A; Dingemans AC
Target Oncol; 2023 Nov; 18(6):821-835. PubMed ID: 37930513
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically Resected Lung Neuroendocrine Neoplasms.
Alì G; Di Stefano I; Poma AM; Ricci S; Proietti A; Davini F; Lucchi M; Melfi F; Fontanini G
Front Oncol; 2021; 11():729765. PubMed ID: 34568063
[TBL] [Abstract][Full Text] [Related]
14. International real-world study of DLL3 expression in patients with small cell lung cancer.
Rojo F; Corassa M; Mavroudis D; Öz AB; Biesma B; Brcic L; Pauwels P; Sailer V; Gosney J; Miljkovic D; Hader C; Wu M; Almarez T; Penault-Llorca F
Lung Cancer; 2020 Sep; 147():237-243. PubMed ID: 32745892
[TBL] [Abstract][Full Text] [Related]
15. Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma.
Xie H; Kaye FJ; Isse K; Sun Y; Ramoth J; French DM; Flotte TJ; Luo Y; Saunders LR; Mansfield AS
Oncologist; 2020 Sep; 25(9):810-817. PubMed ID: 32372416
[TBL] [Abstract][Full Text] [Related]
16. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer.
Saito M; Saito K; Shiraishi K; Maeda D; Suzuki H; Minamiya Y; Kono K; Kohno T; Goto A
Mol Clin Oncol; 2018 Feb; 8(2):310-314. PubMed ID: 29435295
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
[TBL] [Abstract][Full Text] [Related]
18. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer.
Regzedmaa O; Li Y; Li Y; Zhang H; Wang J; Gong H; Yuan Y; Li W; Liu H; Chen J
Onco Targets Ther; 2019; 12():10043-10055. PubMed ID: 31819500
[TBL] [Abstract][Full Text] [Related]
20. Expression patterns and clinical implications of PDL1 and DLL3 biomarkers in small cell lung cancer retrospectively studied: Insights for therapeutic strategies and survival prediction.
Domvri K; Yaremenko AV; Apostolopoulos A; Petanidis S; Karachrysafi S; Pastelli N; Papamitsou T; Papaemmanouil S; Lampaki S; Porpodis K
Heliyon; 2024 Mar; 10(5):e27208. PubMed ID: 38468968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
